tbuckley/cabot-search huggingface dataset:
Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: Issa F. Khouri, Rima M Saliba, Celina Ledesma, Elias J. Jabbour, Francesco Turturro, Gheath Alatrash, Sairah Ahmed, Betul Oran, Krina K Patel, Amanda Olson, David Marin, Uday R. Popat, Tina S Suki, Jeffrey L. Jorgensen, L. Jeffrey Medeiros, Alison M Gulbis
Journal: Blood (2015)
Activation of Chloride Channels with the Anti-Parasitic Agent Ivermectin Induces Membrane Hyperpolarization and Cell Death in Leukemia Cells.
Authors: Sumaiya Sharmeen, Marko Skrtic, Mahadeo Sukhai, Joyce Sun, Rose Hurren, Marcela Gronda, Xiaoming Wang, Tabitha E Wood, Robert A. Batey, Sonali Fonesca, Shana Kelley, Alessandro Datti, Jeff Wrana, Aaron D. Schimmer
Journal: Blood (2009)
PP44. SURGICAL IMPLANTATION OF IRINOTECAN LOADED MICRO-BEADS OFFERS A NOVEL SAFE APPROACH TO TREATING PATIENTS WITH RECURRENT GLIOBLASTOMA(NCT02433392)
Authors: Prof Garth Cruickshank, Dr Oluwafikayo Fayeye, Dr Desire Ngoga, Dr Allah Detta, Dr Andrew Lewis
Journal: Neuro-Oncology (2017)

Glioblastoma Multiforme –(GBM) are infiltrative, impossible to resect totally and consequently recur almost always at the borders of the resection margin. There is no established chemotherapy regimen available to patients who recur. Systemic treatment is hampered by the inability of many therapeutic agents to effectively cross the blood brain barrier and systemic toxicity, hence, loco- regional strategies aim to focus drug delivery within the resected tumour cavity wall. Implantable polymers releasing chemotherapeutic agents into the CNS, such as Gliadel® wafers, are a proven example of this approach. Here we report on the first evaluation in humans of the intraparenchymal injection of microspheres containing the topoisomerase II inhibitor irinotecan (Irinotecan Drug-eluting Beads, or IDEB) into the resection cavity after surgical resection of recurrent GBM. The drug-eluting beads (DEBs) used in this study are composed of a biocompatible biomedical polymer hydrogel loaded with chemotherapeutic agent. This drug delivery system is based on a product that is currently approved and available commercially- DC Beads™ that have a defined release characteristics. Irinotecan itself has demonstrated clinical efficacy in treating glioblastoma but with marked systemic drug-related toxicity. It was therefore considered logical that the combination of these products in the IDEB might offer a useful low-risk alternative therapy for patients, providing an improved method of delivery for an efficacious drug. METHODS: 10 Patients with single focus recurrent GBM Suitable for surgery were selected. 100mg of Irinotecan in 3ml was implanted with ~30 injections into resection margin to a depth of 1 cm in 100μ l per injection. Patients were assessed for clinical toxicity (CTC 3) immediately and over 6/12 for SAE, and MRI changes. Plasma Irinotecan levels and steroid use were recorded RESULTS: 9 patients underwent the treatment. There were no major early or late SAE despite the injection process. Wound healing was unaffected and imaging shows no overt brain swelling unlike other depot therapies. One patient had an increased seizure frequency for a few days. Steroid requirements were not increased overall or by comparison with resection only patients. Median survival was 228days with one patient still surviving. Plasma levels were negligible. CONCLUSION: This novel form of therapy using this bead/drug combination, can be simply and safely delivered to patients following resection for recurrent tumour with low risk of wound problems or tumour/brain swelling at these high concentrations of Irinotecan. Future work will establish a maximally tolerated dose delivered in this way
Abstract P2-07-09: CPM rate among individuals with breast cancer who underwent multiplex gene testing for hereditary cancer: Single institution experience
Authors: N Elsayegh, AM Gutierrez Barrera, HM Kuerer, ND Hernandez, JK Litton, BK Arun
Journal: Cancer Research (2017)

Abstract Background: Availability of multiplex gene (MPG) testing for hereditary cancer has led to increase use of panel testing versus single gene testing for hereditary cancer. These panels include high, but also moderate penetrance genes. For some of these genes, associated cancer risk and risk management guidelines do not exist. Furthermore there is a high rate of variant of unknown significant (VUS) findings in non-BRCA genes. Currently, in the absence or minimal available data, health care providers and patients are faced with important risk management decisions, especially regarding preventive surgeries, such as prophylactic mastectomy. Currently, there is no data regarding prophylactic mastectomy rate among patients with breast cancer who underwent (MPG) testing. Therefore, our aim was to evaluate the rate of contralateral prophylactic mastectomy (CPM) in a cohort of individuals who underwent multiplex gene testing. Methods: Eight hundred thirty five patients with breast cancer who underwent MPG testing between the years 2013 and 2016 were identified using Institutional Clinical Cancer Genetics Database. Patients with pathogenic, likely pathogenic variants or who had a VUS were included in the analysis. Results: Of 835 patients with a diagnosis of breast cancer; 105 (13%) had a pathogenic or likely pathogenic mutation: 29 (28%) BRCA1, 26 (25%) BRCA2, 11 (11%) ATM, 2 (2%) BARD1, 3 (3%) BRIP, 9 (9%) CHEK2, 1 (1%) MSH2, 1 (1%) NBN, 5 (5%) PALB2, 4 (4%) PTEN, 1 (1%) RAD51C, 5 (5%) TP53, 4 (4%) CDH1, 2 (2%) MUTYH, 1 (1%) PMS2, 1 (1%) APC (1). A total of 102 (12%) VUS were found. Average age of diagnosis was 44 (Range 21-81). CPM rate was 32% (n=66) for the total cohort. Twenty nine % (n=19) of patients with non-BRCA mutations, 24.2% (n=16) with VUS and 46% (n=31) with BRCA mutations opted for CPM. Conclusion: Overall 32% of breast cancer patients with germline mutations or VUS opt for CPM at our institution. The rate for CPM in non- BRCA mutations carriers is high despite no available data regarding contralateral breast cancer risk and benefit of CPM. This finding should be validated in larger cohorts, including identification of reasons behind decision for CPM in these cohorts. Citation Format: Elsayegh N, Gutierrez Barrera AM, Kuerer HM, Hernandez ND, Litton JK, Arun BK. CPM rate among individuals with breast cancer who underwent multiplex gene testing for hereditary cancer: Single institution experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-07-09.
Rates of Dermoscopy Use for Melanoma Diagnosis in the Miami VA Medical Center
Authors: Lucy L. Chen, Erin X. Wei, Fangchao Ma, Jonette Keri, Shasa Hu
Journal: JAMA Dermatology (2017)

such as ruxolitinib phosphate, are needed and should continue to elucidate these medications' efficacy, safety, and durability in the treatment of AA.
Social Justice and the Provision of Health Care for Poor Children
Authors: Andrew D. Racine
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Megakaryocytes Do Not Express Erythropoietin Receptor (EpoR) and Do Not Respond to Recombinant Human Erythropoietin (rHuEpo) Stimulation
Authors: Robert D Loberg, John M Rossi, Raffi Manoukian, Shen-Wu Wang, Katherine L Paweletz, Beate Sable, Yanyan Tudor, Scott D Patterson, Ian McCaffery
Journal: Blood (2011)
Abstract P4-02-13: Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions
Authors: S Nakano, K Fujii, J Kousaka, Y Mouri, T Ando
Journal: Cancer Research (2017)

Abstract PURPOSE: Breast ultrasound (US) is a diagnostic imaging modality that is now widely used as an adjunct to mammography for evaluation of breast abnormalities. In the Breast Imaging-Reporting and Data System (BI-RADS) lexicon, a solid mass with an oval shape, well-circumscribed margins and parallel orientation is classified as category 3 (BI-RADS category 3 mass lesions) . This mass should have a risk of malignancy of &amp;lt; 2%. Surveillance breast US in short-interval follow-up for BI-RADS category 3 mass lesions is an acceptable alternative to biopsy. The surveillance US is recommended 6 month after initial lesion identification and then every year for at least 2 y. However, inconsistent reproducibility for US due to operator dependence is still a clinical issue. The aim of our study was to verify the utility of US using real-time virtual sonography (RVS) - to coordinate present US images with past US images reconstructed from previously acquired US volume data using magnetic tracking system – in a short-interval follow--up for BI-RADS category 3 mass lesions. METHOD AND MATERIALS: We enrolled 20 women (23 lesions) with more than 24 months of follow-up after classification as BI-RADS category 3 during initial US. US surveillance was scheduled at 6, 12 and 24 months. Three-dimensional assessment of morphologic features was performed while serially checking past US volume data corresponding to the present US probe position. Measurement of the target lesion diameter was performed after the probe was adjusted to include the maximum diameter of a past US image at each visit. RESULTS: RVS was technically successful in 100% of patients. All target lesions were detected, including two iso-echoic lesions. The mean target lesion diameters at baseline and at 6, 12 and 24 months were 8.2+4.2, 8.4+4.5, 8.1+4.5 and 8.3+5.0 mm, respectively . Statistical analysis using a Friedman test with multiple comparisons revealed no significant difference between the diameters at each time point (p = 0.785). RVS was used to directly compare the US morphologic characteristics and sized of lesions. Furthermore, the RVS data can be reproduced in their entirety for independent review at a later date by using stored US volume data. CONCLUSION:Our results suggest that RVS is reproducible, operator-independent technique for comparison of US images of BI-RADS category 3 mass lesions obtained at different time points. Citation Format: Nakano S, Fujii K, Kousaka J, Mouri Y, Ando T. Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-02-13.
Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.
Authors: Francis J. Giles, Farhad Ravandi, Jorge Cortes, Zeev Estrov, Stefan Faderl, Alessandra Ferrajoli, Guillermo Garcia-Manero, Deborah Thomas, William Wierda, Srdan Verstovsek
Journal: Blood (2006)
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress
Authors: Katrin F. Chua, Raul Mostoslavsky, David B. Lombard, Wendy W. Pang, Shin'ichi Saito, Sonia Franco, Dhruv Kaushal, Hwei-Ling Cheng, Miriam Fischer, Nicole Stokes, Michael M. Murphy, Ettore Appella, Frederick W. Alt
Journal: Cell Metabolism (2006)
Abstract P3-08-02: Multi-gene panel testing for hereditary cancer predisposition in unsolved high risk breast and ovarian cancer patients
Authors: BB Crawford, SB Adams, T Sittler, J Van den Akker, SB Chan, O Leitner, LN Ryan, E Gil, LJ Van 't Veer
Journal: Cancer Research (2017)

Abstract Background Among women with an elevated risk of hereditary breast and ovarian cancer who previously tested negative for pathogenic mutations in BRCA1 and BRCA2, a subset remain at increased risk of having hereditary breast, ovarian or other cancers, and should be offered multi-gene panel testing. We tested three groups of women who were enrolled in the UCSF Cancer Genetics and Prevention Program: (i) 97 women with a personal history of bilateral breast cancer, (ii) 104 women with a personal history of breast cancer and a first-degree or second-degree relative with ovarian cancer, and (iii) 99 women with a personal history of ovarian, fallopian tube, or primary peritoneal cancer. All women previously tested negative for pathogenic BRCA1 and BRCA2 mutations by either limited or comprehensive testing. Methods We performed comprehensive next-generation sequencing using a panel of 19 genes developed by Color Genomics (a CLIA-certified laboratory) covering ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53. Results Across the groups tested, 9% had pathogenic mutations in one or more of the genes analyzed (8% in genes other than BRCA1 and BRCA2). Among these women, Ashkenazi Jewish and Hispanic women had elevated mutation rates compared to those of other ethnicities. In addition, we identified two women with pathogenic mutations in two cancer susceptibility genes, which has significant implications for family testing. These results demonstrate the importance of genetic testing of genes other than BRCA1 and BRCA2. Conclusions Among women with an elevated risk of hereditary breast and ovarian cancer who have previously tested negative for BRCA1 and BRCA2 mutations, we propose that women with characteristics of any of the three groups above be considered for subsequent multi-gene panel testing. Additionally, ethnicity and the possibility of multiple mutations may be indications for additional testing in these women and in family members of carriers. Citation Format: Crawford BB, Adams SB, Sittler T, Van den Akker J, Chan SB, Leitner O, Ryan LN, Gil E, Van 't Veer LJ. Multi-gene panel testing for hereditary cancer predisposition in unsolved high risk breast and ovarian cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-08-02.
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
Authors: Karen M. Mustian, Catherine M. Alfano, Charles Heckler, Amber S. Kleckner, Ian R. Kleckner, Corinne R. Leach, David Mohr, Oxana G. Palesh, Luke J. Peppone, Barbara F. Piper, John Scarpato, Tenbroeck Smith, Lisa K. Sprod, Suzanne M. Miller
Journal: JAMA Oncology (2017)

Cancer-related fatigue (CRF) remains one of the most prevalent and troublesome adverse events experienced by patients with cancer during and after therapy.To perform a meta-analysis to establish and compare the mean weighted effect sizes (WESs) of the 4 most commonly recommended treatments for CRF-exercise, psychological, combined exercise and psychological, and pharmaceutical-and to identify independent variables associated with treatment effectiveness.PubMed, PsycINFO, CINAHL, EMBASE, and the Cochrane Library were searched from the inception of each database to May 31, 2016.Randomized clinical trials in adults with cancer were selected. Inclusion criteria consisted of CRF severity as an outcome and testing of exercise, psychological, exercise plus psychological, or pharmaceutical interventions.Studies were independently reviewed by 12 raters in 3 groups using a systematic and blinded process for reconciling disagreement. Effect sizes (Cohen d) were calculated and inversely weighted by SE.Severity of CRF was the primary outcome. Study quality was assessed using a modified 12-item version of the Physiotherapy Evidence-Based Database scale (range, 0-12, with 12 indicating best quality).From 17 033 references, 113 unique studies articles (11 525 unique participants; 78% female; mean age, 54 [range, 35-72] years) published from January 1, 1999, through May 31, 2016, had sufficient data. Studies were of good quality (mean Physiotherapy Evidence-Based Database scale score, 8.2; range, 5-12) with no evidence of publication bias. Exercise (WES, 0.30; 95% CI, 0.25-0.36; P < .001), psychological (WES, 0.27; 95% CI, 0.21-0.33; P < .001), and exercise plus psychological interventions (WES, 0.26; 95% CI, 0.13-0.38; P < .001) improved CRF during and after primary treatment, whereas pharmaceutical interventions did not (WES, 0.09; 95% CI, 0.00-0.19; P = .05). Results also suggest that CRF treatment effectiveness was associated with cancer stage, baseline treatment status, experimental treatment format, experimental treatment delivery mode, psychological mode, type of control condition, use of intention-to-treat analysis, and fatigue measures (WES range, -0.91 to 0.99). Results suggest that the effectiveness of behavioral interventions, specifically exercise and psychological interventions, is not attributable to time, attention, and education, and specific intervention modes may be more effective for treating CRF at different points in the cancer treatment trajectory (WES range, 0.09-0.22).Exercise and psychological interventions are effective for reducing CRF during and after cancer treatment, and they are significantly better than the available pharmaceutical options. Clinicians should prescribe exercise or psychological interventions as first-line treatments for CRF.
Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party
Authors: Kavita Raj, Eduardo Olavarria, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Maria Teresa van Lint, Fabio Ciceri, Jakob Passweg, Nicolaas PM Schaap, Kristina Carlson, Didier Blaise, Stella Santarone, Antonin Vitek, Jose L. Diez-Martin, Donal McLornan, Marie Robin, Yves Chalandon, Nicolaus Kroeger
Journal: Blood (2016)
Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): Report of 11 Cases.
Authors: Juan-Manuel Sancho, Anne Parker, Guillermo Deben, Simon Bolam, Eugenio Gimenez, Eva Sanchez-Garcia, Jose-Luis Piñana, Teresa Pascual, Carmen Mateos, Pascual Fernandez-Abellan, Luis Palomera, Josep-Maria Ribera
Journal: Blood (2006)
Correction: Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
Authors: Junjian Wang, June X Zou, Xiaoqian Xue, Demin Cai, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C Yang, Maggie C Louie, Alexander D Borowsky, Allen C Gao, Christopher P Evans, Kit S Lam, Jianzhen Xu, Hsing-Jien Kung, Ronald M Evans, Yong Xu, Hong-Wu Chen
Journal: Nature Medicine (2016)
Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.
Authors: Dong-Wook Kim, Dongho Kim, Soo-Hyun Kim, Hyun-Gyung Goh, Fabrizio Pane, Timothy Hughes, Jerald P. Radich, Peter Lin, Giuseppe Saglio, Susan Branford, Giovanni Martinelli, Simona Soverini, Andreas Hochhaus
Journal: Blood (2010)
Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.
Authors: Bronwen E. Shaw, Jenny L. Byrne, Emma Das-Gupta, Ian Carter, Nigel H. Russell
Journal: Blood (2005)
American College of Rheumatology/European League Against Rheumatism Sjögren's Syndrome Classification Criteria May Not Be Adequate for Extraglandular Disease and Necessitate Defining “Seronegative Sjögren's Syndrome”: Comment on the Article by Shiboski et al
Authors: Mehmet E. Tezcan, Hamit Kucuk, Berna Goker
Journal: Arthritis & Rheumatology (2017)
Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity
Authors: Mark J.G. Bakkers, Yifei Lang, Louris J. Feitsma, Ruben J.G. Hulswit, Stefanie A.H. de Poot, Arno L.W. van Vliet, Irina Margine, Jolanda D.F. de Groot-Mijnes, Frank J.M. van Kuppeveld, Martijn A. Langereis, Eric G. Huizinga, Raoul J. de Groot
Journal: Cell Host & Microbe (2017)
Abstract P4-21-21: Her2 is not a cancer subtype but rather a driver found in all intrinsic subtypes and highly enriched in molecular apocrine tumors
Authors: A Daemen, G Manning
Journal: Cancer Research (2017)

Abstract Her2-enriched (Her2E) breast tumors defined by molecular profiling are discrepant from Her2-amplified tumors defined by clinical assessment – over half of all Her2-amplified tumors are not Her2E, while one-third of Her2E tumors are not Her2-amplified. We explored this discordance using genomic profiles of 4,000 breast tumors. We find clear support that Her2 amplification is a discrete cancer driver event and not a subtype, with little genomic impact other than in expression of genes on the amplicon. Many Her2-amplified tumors clearly belong to the basal, luminal A, or luminal B subtypes. After accounting for the Her2 amplicon, most tumors classified as Her2E appear to be molecular apocrine, expressing high levels of androgen receptor and low to moderate levels of ER. The high rate of Her2 amplification in this group (63%) suggests that additional growth drivers are required for molecular apocrine tumors. Her2 amplification is also a driver across subtypes of several non-breast tumor types. Her2 is amplified in 2% of 5,400 non-breast tumors, spanning 23 tumor types. The Her2 region in non-breast cancers shows a similar range of amplification and breadth of the amplicon, and a comparable rate of overexpression of genes within the amplicon for most Her2A tumors. These discoveries reveal therapeutic opportunities for combining anti-Her2 therapy with endocrine or anti-androgen agents for breast cancer, and for expanding anti-Her2 therapy to other tumor types. Citation Format: Daemen A, Manning G. Her2 is not a cancer subtype but rather a driver found in all intrinsic subtypes and highly enriched in molecular apocrine tumors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-21.